会计年度:2015-12-31收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 化学合成药 | 105,107,211.83 | 75,096,179.99 | 30,011,031.84 | 28.55 |
| 生物制品 | 375,615,474.32 | 42,316,515.73 | 333,298,958.59 | 88.73 |
| 医疗服务 | 7,835,711.13 | 14,249,209.65 | -6,413,498.52 | -81.85 |
| 中成药 | 145,327,519.97 | 48,511,829.68 | 96,815,690.29 | 66.62 |
|
会计年度:2015-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 安徽 | 34,462,521.70 | 8,540,868.20 | 25,921,653.50 | 75.22 |
| 干扰素 | 83,576,665.68 | 15,126,968.00 | 68,449,697.68 | 81.90 |
| 国内销售： | 281,006,725.20 | 86,015,834.69 | 194,990,890.51 | 69.39 |
| 国外销售： | 13,073,747.59 | 1,689,212.71 | 11,384,534.88 | 87.08 |
| 华北东北 | 36,780,377.60 | 16,751,444.10 | 20,028,933.50 | 54.46 |
| 华东（不含安徽） | 107,531,087.35 | 36,093,604.93 | 71,437,482.42 | 66.43 |
| 华南 | 39,322,687.88 | 9,652,499.72 | 29,670,188.16 | 75.45 |
| 华中西南 | 57,968,080.61 | 13,873,798.71 | 44,094,281.90 | 76.07 |
| 化学合成药 | 55,011,703.60 | 39,475,474.83 | 15,536,228.77 | 28.24 |
| 活血止痛膏 | 44,910,706.76 | 11,353,091.57 | 33,557,615.19 | 74.72 |
| 其他 | 77,994,114.33 | 55,067,362.73 | 22,926,751.60 | 29.40 |
| 生长激素 | 87,598,986.02 | 6,157,625.10 | 81,441,360.92 | 92.97 |
| 生物制品 | 177,490,037.13 | 21,851,150.37 | 155,638,886.76 | 87.69 |
| 西北 | 4,941,970.06 | 1,103,619.03 | 3,838,351.03 | 77.67 |
| 医疗服务 | 6,702,214.19 | 9,726,008.04 | -3,023,793.85 | -45.12 |
| 中成药 | 54,876,517.87 | 16,652,414.16 | 38,224,103.71 | 69.65 |
|
会计年度:2014-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 化学合成药 | 94,617,565.26 | 67,829,158.47 | 26,788,406.79 | 28.31 |
| 生物制品 | 314,079,043.56 | 39,224,419.64 | 274,854,623.92 | 87.51 |
| 医疗服务 | 12,532,308.95 | 13,188,998.11 | -656,689.16 | -5.24 |
| 中成药 | 120,135,822.53 | 36,509,785.68 | 83,626,036.85 | 69.61 |
|
会计年度:2014-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 安徽 | 26,585,416.21 | 8,353,608.98 | 18,231,807.23 | 68.58 |
| 干扰素 | 71,298,397.54 | 15,038,163.00 | 56,260,234.54 | 78.91 |
| 国内销售： | 211,879,462.22 | 63,731,213.71 | 148,148,248.51 | 69.92 |
| 国外销售： | 15,421,587.09 | 2,636,485.17 | 12,785,101.92 | 82.90 |
| 华北东北 | 28,142,377.73 | 8,430,864.90 | 19,711,512.83 | 70.04 |
| 华东（不含安徽） | 75,622,595.12 | 26,942,665.95 | 48,679,929.17 | 64.37 |
| 华南 | 29,553,284.15 | 8,054,171.47 | 21,499,112.68 | 72.75 |
| 华中西南 | 47,533,490.93 | 10,967,807.86 | 36,565,683.07 | 76.93 |
| 化学合成药 | 37,821,313.40 | 27,250,761.14 | 10,570,552.26 | 27.95 |
| 活血止痛膏 | 39,295,690.40 | 10,353,013.37 | 28,942,677.03 | 73.65 |
| 其他 | 53,492,903.56 | 35,127,649.91 | 18,365,253.65 | 34.33 |
| 生长激素 | 63,214,057.81 | 5,848,872.60 | 57,365,185.21 | 90.75 |
| 生物制品 | 139,034,632.98 | 21,278,304.54 | 117,756,328.44 | 84.70 |
| 西北 | 4,442,298.08 | 982,094.55 | 3,460,203.53 | 77.89 |
| 医疗业务 | 1,523,409.34 | 1,754,660.73 | -231,251.39 | -15.18 |
| 中成药 | 48,921,693.59 | 16,083,972.47 | 32,837,721.12 | 67.12 |
|
会计年度:2013-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 医药制造业 | 429,193,414.46 | 116,543,655.19 | 312,649,759.27 | 72.85 |
|
3/5 转到 
